PTK7 expression is associated with lymph node metastasis, ALK and EGFR mutations in lung adenocarcinomas.

PTK7 expression is associated with lymph node metastasis, ALK and EGFR mutations in lung adenocarcinomas. Histol Histopathol. 2019 Nov 08;:18183 Authors: Jiang W, He J, Lv B, Xi X, He G, He J Abstract Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer death worldwide. Lung adenocarcinoma is the main tumor type of NSCLC. Recent advances in the molecular characterization and personalized therapies have improved NSCLC patient prognosis. Previous studies showed that protein tyrosine kinase 7 (PTK7) plays an important role in human cancers. However, the role of PTK7 has not been investigated. PTK7 expression was assessed by immunohistochemistry in 95 patients with lung adenocarcinoma. Correlations of PTK7 expression levels with clinicopathological parameters, EGFR mutation and EML4-ALK fusion were examined. Positive PTK7 expression was detected in 47.4% of lung adenocarcinoma. PTK7 expression was associated with gender (P=0.024), lymph node metastasis (P
Source: Histology and Histopathology - Category: Cytology Tags: Histol Histopathol Source Type: research

Related Links:

In conclusion, we suggest molecular profiling of progressive tumor disease also for ALK-positive NSCLC to personalize treatment in a subgroup of ALK-positive patients.PMID:34548910 | PMC:PMC8448518 | DOI:10.18632/oncotarget.28062
Source: Oncotarget - Category: Cancer & Oncology Authors: Source Type: research
Adenocarcinoma and squamous cell carcinoma are the two most prevalent lung cancer types, and their distinction requires different screenings, such as the visual inspection of histology slides by an expert path...
Source: BMC Bioinformatics - Category: Bioinformatics Authors: Tags: Research Source Type: research
Conclusion: Serum level of plasma HSP90 α could be a reliable biomarker in diagnosing lung cancer and its subtypes and might be a valid biomarker for predicting lung cancer relapse in patients treated with chemoradiotherapy and surgery.Oncol Res Treat
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
A 65-year-old woman with prolonged cough and presumed pulmonary hypertrophic osteoarthropathy was referred to our hospital. Computed tomography showed 2 tumors larger than 3 cm in size and massive hilar lymph node enlargement in the right lung. Pathological examination of the transbronchial lung biopsy specimen showed atypical malignant cells, presumed adenocarcinoma, with 1% positivity of programmed cell death 1 ligand (PD-L1). Three courses of chemoimmunotherapy with pembrolizumab (400 mg q3w), carboplatin (AUC 5 mg/mL · min q3w), and pemetrexed (500 mg/m2 q3w) were well tolerated and brought about a quasi-complete resp...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
AbstractObjectiveTo study the mechanism of Chinese herbal medicine Fuzheng Kang ’ai Formula (扶正抗癌方, FZKA) on tumor microenvironment (TME).MethodsCIBERSORTx was used for analysis of TME. Traditional Chinese Medicine Systems Pharmacology and Analysis Platform was applied to identify compounds-targets network and the Cancer Genome Atlas (TCGA) was employed to identify the differential expression genes (DEGs) between tumor and paracancerous tissues in lung adenocarcinoma (LUAD) from TCGA-LUAD. Additionally, DEGs with prognosis in LUAD was calculated by univariable and multivariate Cox regression. The core targe...
Source: Chinese Journal of Integrative Medicine - Category: Internal Medicine Source Type: research
CONCLUSION: Therapy-related acute myeloid neoplasm (t-MN) is a rare but fatal late complication. Although a patient may be taking EGFR-TKIs, the possibility of t-MN should be considered. Further studies are needed to determine whether EGFR-TKI usage is a predisposing factor for t-MN.PMID:34540979 | PMC:PMC8409203 | DOI:10.12998/wjcc.v9.i24.7205
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
In this study, using a proteomic approach, we revealed important targets and signaling pathways altered in cisplatin-resistant A549 lung adenocarcinoma cells. STAT3 had increased expression in a resistance context, which can be associated with a poor prognosis. STAT3 knockout (SKO) resulted in a decreased mesenchymal phenotype in A549 cells, observed by clonogenic potential and by the expression of epithelial-mesenchymal transition markers. Importantly, SKO cells did not acquire the mTOR pathway overactivation induced by cisplatin resistance. Consistently, SKO cells were more responsive to mTOR inhibition by rapamycin and ...
Source: Neoplasia - Category: Cancer & Oncology Authors: Source Type: research
Lung cancer is an important part of malignant tumors, with an annual incidence of 1,796,144 new deaths and 2,206,771 new cases in 2020 all over the world [1]. As the common histological type of lung cancer, non-small-cell lung cancer (NSCLC) mainly consists of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) [2]. For early stage NSCLC patients, curative-intent anatomic surgical resection is the standard of treatment strategy, whereas the onset of recurrence and metastasis after surgery often results in treatment failure and mortality [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and cataly...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cytology | Lung Cancer | Non-Small Cell Lung Cancer | Study